Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 4
2006 1
2007 5
2008 10
2009 12
2010 15
2011 14
2012 13
2013 16
2014 24
2015 20
2016 23
2017 24
2018 24
2019 21
2020 27
2021 25
2022 21
2023 26
2024 25
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Results by year

Filters applied: . Clear all
Page 1
Estimated Effect of Restarting Renin-Angiotensin System Inhibitors after Discontinuation on Kidney Outcomes and Mortality.
Hattori K, Sakaguchi Y, Oka T, Asahina Y, Kawaoka T, Doi Y, Hashimoto N, Kusunoki Y, Yamamoto S, Yamato M, Yamamoto R, Matsui I, Mizui M, Kaimori JY, Isaka Y. Hattori K, et al. Among authors: kawaoka t. J Am Soc Nephrol. 2024 Oct 1;35(10):1391-1401. doi: 10.1681/ASN.0000000000000425. Epub 2024 Jun 18. J Am Soc Nephrol. 2024. PMID: 38889205
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL. Lau G, et al. Among authors: kawaoka t. J Hepatol. 2025 Feb;82(2):258-267. doi: 10.1016/j.jhep.2024.07.017. Epub 2024 Jul 31. J Hepatol. 2025. PMID: 39089633 Free article. Clinical Trial.
Reply from the authors.
Kawaoka T, Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chayama K, Aikata H. Kawaoka T, et al. Hepatol Res. 2020 Dec;50(12):1393. doi: 10.1111/hepr.13578. Hepatol Res. 2020. PMID: 33280200 No abstract available.
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP-012 investigators. Kudo M, et al. Among authors: kawaoka t. Lancet. 2025 Jan 18;405(10474):203-215. doi: 10.1016/S0140-6736(24)02575-3. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798578 Clinical Trial.
Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma.
Shirane Y, Fujii Y, Ono A, Nakahara H, Hayes CN, Miura R, Murakami S, Sakamoto N, Uchikawa S, Fujino H, Nakahara T, Murakami E, Yamauchi M, Miki D, Kawaoka T, Arihiro K, Tsuge M, Oka S. Shirane Y, et al. Among authors: kawaoka t. Cancers (Basel). 2024 Mar 28;16(7):1328. doi: 10.3390/cancers16071328. Cancers (Basel). 2024. PMID: 38611007 Free PMC article.
Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.
Miura R, Ono A, Yano S, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Kawaoka T, Miki D, Tsuge M, Hayes CN, Oka S. Miura R, et al. Among authors: kawaoka t. Medicine (Baltimore). 2024 Aug 23;103(34):e39289. doi: 10.1097/MD.0000000000039289. Medicine (Baltimore). 2024. PMID: 39288227 Free PMC article.
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
Kinami T, Uchikawa S, Kawaoka T, Yamasaki S, Kosaka M, Johira Y, Yano S, Amioka K, Naruto K, Yamaoka K, Fujii Y, Fujino H, Nakahara T, Ono A, Murakami E, Okamoto W, Yamauchi M, Miki D, Tsuge M, Oka S. Kinami T, et al. Among authors: kawaoka t. Cancer Med. 2024 Mar;13(5):e7025. doi: 10.1002/cam4.7025. Cancer Med. 2024. PMID: 38477514 Free PMC article.
310 results